Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne (NCT00706433), a randomized phase 2 study. The primary outcome is Change in Inflammatory Lesion Counts Relative to Baseline.

2. Clinical Question

3. Trial Design

This was a randomized, double-masked, parallel-group phase 2 study. The official title describes it as evaluator-blinded. The registry reports enrollment of 266 and a completed study. It lists a start in 2007-03 and primary completion in 2008-07. The registry record does not report the allocation ratio, the details of sequence generation, or how masking was maintained.

There were four treatment arms. Aminolevulinic acid HCL was applied to the entire facial area 45 minutes before blue light in the 1000-second and 500-second arms. Vehicle was applied in the same way in the corresponding vehicle arms. Thus, the active preparation and vehicle were each studied with two blue-light exposure durations. The registry identifies Vehicle 1000 Seconds as the control group for the posted outcome results.

The study purpose was to determine and compare safety and efficacy of multiple broad-area photodynamic therapy treatments using aminolevulinic acid or vehicle in moderate to severe facial acne vulgaris. The primary outcome population is described as ITT analysis, LOCF. The primary outcome timeframe is baseline and 3 weeks after final treatment. The registry record does not state the number of treatment visits, a detailed visit schedule, or the rationale for the selected exposure durations.

The recorded enrollment describes the study as a whole; arm-specific outcome counts are reported separately for the primary endpoint. The record lists 77 outcome measures and 142 analyses, indicating that many outcomes or analyses were registered. It does not provide a complete account of how all such outcomes were tested or how they relate to the primary analysis.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: no enrolled participants excluded from the trial before assignment to groups

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: ITT analysis, LOCF

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change in Inflammatory Lesion Counts Relative to Baseline, measured over Baseline and 3 weeks after final treatment.

The primary endpoint is change in inflammatory lesion counts relative to baseline, assessed at baseline and 3 weeks after final treatment. Inflammatory lesion counts quantify a specified aspect of acne severity. Tracking the change from baseline focuses on how the count differs from each participant’s starting measurement, rather than relying only on a final count that may reflect differences in starting severity.

The registry labels the summary parameter as a median and gives a standard deviation as the dispersion measure. It reports arm-level values of -18.0 for ALA 1000 Seconds, -14.0 for ALA 500 Seconds, -19.0 for Vehicle 1000 Seconds, and -14.5 for Vehicle 500 Seconds. These are negative changes in lesion count, as expected from the direction implied by a change measure when counts decline. The posted results do not give confidence intervals for these arm-level values.

In general, a baseline-to-follow-up change measure can describe the direction and size of change over the stated period, while the comparison between randomized groups addresses whether their observed outcomes differ statistically. Those are distinct questions. The arm summaries describe the observed changes; the reported ANCOVA result is the registry’s inferential comparison across all four groups. A median and standard deviation describe different features of a distribution: the median gives its central position, while the standard deviation characterizes spread. The registry does not explain why it presents that combination for this endpoint.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does the ANCOVA result compare?

ANCOVA, or analysis of covariance, is a general method for comparing group outcomes while accounting for one or more covariates. In randomized trials, a baseline measurement is often a covariate, but the registry does not report which covariates were used in this study. The reported analysis includes all four treatment groups and gives p = 0.768. This is a group-level result; it does not supply separate estimates for each active-treatment arm versus its corresponding vehicle arm.

In general, a p-value summarizes how compatible the observed data are with a specified statistical model under a null hypothesis. It does not give the probability that the null hypothesis is true, nor does it measure the size or practical importance of an effect. A p-value also does not replace an estimate with a confidence interval. The registry reports no confidence interval or effect estimate from the ANCOVA, so the precision of the adjusted group comparison cannot be read directly from the reported p-value.

How should the endpoint summaries be read?

The endpoint is a change in inflammatory lesion counts, and the registry identifies the summary parameter as the median. The median is the midpoint of an ordered set of observations: it is a measure of the distribution’s center and is less influenced by extreme observations than the arithmetic mean. The registry also reports standard deviations. In general, the standard deviation describes the spread of individual observations around a mean, so it is not a direct measure of uncertainty in a median. Because the record does not explain this reporting choice or show the participant-level distribution, interpretation of the dispersion values should remain cautious.

The arm-level summaries are descriptive statistics. They do not, by themselves, show whether an observed difference between arms is compatible with random variation or how precisely that difference is estimated. For those questions, readers would generally look for a treatment contrast and its confidence interval, alongside the analysis method. Those contrast estimates and intervals are not reported in the registry record.

What does the analysis population mean?

The registry describes the primary endpoint population as ITT analysis, LOCF. In general, an intention-to-treat approach aims to analyze participants according to their randomized groups, preserving the comparison created by randomization. LOCF means last observation carried forward: when a later measurement is missing, an earlier observed value may be used in its place. This approach can impose assumptions about what happened after the last observation, and those assumptions may not reflect the unobserved outcome. The registry does not provide the number of missing values, the timing or reasons for missingness, or enough detail to assess how LOCF affected these results.

Missing-data methods matter because the interpretation of an endpoint depends not only on observed measurements but also on how missing measurements are handled. In general, carrying an earlier value forward can make an analysis appear more complete while potentially understating or overstating subsequent change, depending on the actual unobserved outcomes. This is a general statistical limitation, not evidence that the method biased this trial’s result in a particular direction.

What can be inferred from a four-group test?

A four-group analysis can test an overall group effect without identifying which specific groups differ. If a study has several treatment arms, an overall test and pairwise comparisons answer related but different questions. A group-level p-value cannot establish the direction or size of every possible contrast. The registry reports no pairwise estimates, confidence intervals, or separate pairwise p-values for the primary endpoint.

In general, examining many outcomes and contrasts can raise multiplicity concerns: the more statistical questions considered, the greater the chance that some findings may appear noteworthy by chance if no adjustment or prespecified hierarchy is used. The registry lists 77 outcome measures and 142 analyses, but it does not report a multiplicity strategy or identify a hierarchy for interpreting the primary and secondary results. The number of registered outcomes alone does not show that all were tested in the same way or that a particular adjustment was or was not used.

The record includes planning-illustration assumptions based on the observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. Such illustrations are not observed power and do not establish the trial’s original design justification. The registry record does not report the protocol’s sample-size justification or a prospective sample-size calculation. No arm-specific planning-illustration values are stated in the registry entries used for this interpretation.

10. Analyses Reported by the Sponsor

The registry reports the sponsor’s primary analysis as an ANCOVA across the four groups, with p = 0.768. It does not provide an adjusted effect estimate, a confidence interval, or pairwise contrasts from that analysis. The posted arm summaries are medians with standard deviations, and the record does not contain the information needed to reconstruct the adjusted ANCOVA result from those summaries.

No separate recalculated two-arm estimate for the primary endpoint is reported in the registry record. The available information therefore does not support a direct numerical comparison between the sponsor’s four-group model and an unadjusted recalculation. The record does not flag a discrepancy between a sponsor result and a recalculated result. This absence of a flagged discrepancy should not be read as independent confirmation of the model: the underlying estimates and sufficient model details are not reported.

For interpretation, the sponsor’s posted analysis remains the available inferential result. Its p-value should be read as a four-group test, not as an adjusted comparison of any single ALA arm with a vehicle arm. The lack of reported contrasts limits how specifically the analysis can answer those treatment-comparison questions.

11. Multiplicity, Missing Data and Analysis Populations

The registry lists 77 outcome measures and 142 analyses, while the information available for the primary endpoint gives one four-group ANCOVA result. A large set of outcomes and analyses can create multiplicity: when many statistical questions are asked, some results may look unusual by chance. In general, trials can address this through prespecified primary outcomes, ordered testing strategies, or adjustments to inference. The registry record does not report whether such a strategy was planned or used, or how the primary outcome was prioritized relative to secondary outcomes.

The registry lists secondary outcomes that include percent change in inflammatory lesion counts, subject satisfaction, change in lesion counts, investigator global assessment successes, and hyperpigmentation at specified assessments. The record does not provide enough detail to interpret all secondary results or determine which were prespecified as confirmatory. The number of analyses listed is not itself evidence that the reported primary result is invalid, but it is a reason to distinguish the primary analysis from exploratory findings and to seek the protocol or analysis plan for context.

The primary population is described as ITT analysis, LOCF. In general, intention-to-treat analysis preserves assignment to randomized groups, while LOCF fills a missing follow-up measurement with a prior observation. The registry does not report the amount or pattern of missing data, the reasons observations were missing, or sensitivity analyses using alternative missing-data assumptions. It also does not give participant flow by reason for withdrawal or a detailed description of which participants contributed to each analysis.

The study enrollment is 266, and the primary endpoint summaries include arm-specific counts. The record does not state whether every randomized participant contributed an endpoint value or explain differences between enrollment and outcome-analysis counts. It also does not report a statistical analysis plan, prospective sample-size justification, or interim-analysis plan. These omissions limit assessment of prespecification, precision planning, and the robustness of findings to missing data and multiple testing.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The registry reports zero participants affected by serious adverse events in each of the four arms: ALA 1000 Seconds, ALA 500 Seconds, Vehicle 1000 Seconds, and Vehicle 500 Seconds. The corresponding numbers at risk are 68, 65, 67, and 66. These are the posted serious-adverse-event counts for the groups and should be read as recorded event information, not as proof that serious harms could not occur.

The registry does not list serious adverse-event terms. Death counts are not reported in the registry record. For other adverse events, the record gives affected counts of 35, 38, 19, and 22 across the four arms, but the numbers at risk for those entries are not reported. Without those denominators, the other-event counts should not be converted into rates or compared as if their exposure information were complete.

Safety summaries describe events recorded during the study; they do not establish the cause of an event or resolve uncertainty about uncommon outcomes. The posted counts also do not provide details on event severity, timing, duration, or relationship to treatment. They should therefore be interpreted as a limited registry summary rather than a complete safety profile.

13. What the Result Does, and Does Not, Mean

The primary endpoint describes change in inflammatory lesion counts from baseline to 3 weeks after final treatment. The reported arm-level medians are -18.0 for ALA 1000 Seconds, -14.0 for ALA 500 Seconds, -19.0 for Vehicle 1000 Seconds, and -14.5 for Vehicle 500 Seconds. The sponsor-reported four-group ANCOVA result is p = 0.768. These posted results do not show a clear statistical separation among the four arms on the primary endpoint.

This finding does not establish that the treatment regimens have identical effects. A lack of a statistically clear group separation is not the same as proof of equivalence or non-inferiority. The registry does not report a prespecified equivalence or non-inferiority framework, and it gives no confidence intervals for treatment contrasts. It is therefore not possible to use the reported p-value alone to rule out potentially meaningful differences.

The result also does not identify whether a particular light exposure duration or topical preparation is associated with a different outcome. The four-arm test is not accompanied by pairwise contrasts, so the registry does not show the adjusted comparison of ALA 1000 Seconds with Vehicle 1000 Seconds, or ALA 500 Seconds with Vehicle 500 Seconds. The reported arm summaries are descriptive and do not substitute for those inferential comparisons.

More broadly, the registry record does not provide the detailed model specification, missing-data sensitivity analyses, complete participant flow, or multiplicity plan needed for a fuller assessment of robustness. It also does not report sufficient safety detail to characterize event rates for all adverse-event categories. These limitations define what can be concluded from the posted information; they do not demonstrate that unreported analyses or details were absent from the full study documentation.

The appropriate reading is therefore narrow: the registry posts a four-group ANCOVA result that does not indicate a clear statistical difference on the primary outcome, alongside similar descriptive central values and notable within-arm spread. The evidence presented does not establish equality, quantify the precision of specific treatment contrasts, or determine the clinical importance of possible differences.

14. Why This Trial Matters Statistically

This trial is statistically informative because it includes four randomized groups that vary the topical preparation and blue-light exposure duration. That structure creates more than one relevant comparison: an overall comparison across all groups, and specific comparisons between active-treatment and vehicle arms at each exposure duration. The registry reports an overall ANCOVA result but no pairwise contrasts. This distinction illustrates why a single group-level p-value may not answer every treatment question readers have.

The primary endpoint is a change measure, summarized with medians and standard deviations, while the reported inferential method is ANCOVA. This combination highlights the importance of knowing precisely what the model estimates and how its assumptions relate to the reported summaries. The registry does not report enough model detail to resolve those questions, so the analysis cannot be fully reconstructed from the posted summary statistics.

The study also illustrates how missing-data handling affects interpretation. The primary population is identified as ITT with LOCF, but the amount and pattern of missingness and the sensitivity of results to alternative assumptions are not reported. In general, the chosen approach to missing observations can shape a change-from-baseline comparison, making transparent reporting of missingness and sensitivity analyses important.

Finally, the record lists many outcome measures and analyses without describing a multiplicity plan. That makes it useful to distinguish the primary result from other analyses and to avoid treating every reported finding as equally confirmatory. Overall, the statistical lesson is not about declaring a treatment effect, but about reading the estimand, comparison, uncertainty, missing-data approach, and scope of inference together.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record does not report confidence intervals for the arm summaries or the four-group ANCOVA, nor does it provide adjusted contrasts between individual arms. This limits assessment of the range of effects compatible with the data and prevents a direct interpretation of the specific ALA-versus-vehicle comparisons at each light duration. The overall p-value alone cannot supply that information.

The model description is brief. Although ANCOVA is named, the covariates, model specification, assumptions, and exact parameter tested are not reported in the registry record. The endpoint is labeled as a median with standard deviation, but the record does not explain the relationship between that summary and the reported analysis. The underlying participant-level data are not included in the registry record for this interpretation, so the calculation and model fit cannot be independently assessed.

The primary analysis is described as ITT with LOCF, but missing-data counts, reasons, patterns, and sensitivity analyses are not reported. The record also does not detail participant flow or explain differences between enrollment and endpoint-analysis counts. These omissions make it difficult to evaluate how missing outcomes might have affected the result.

The study has four arms and the record lists 77 outcome measures and 142 analyses, but no multiplicity plan is reported. The protocol’s sample-size justification, interim-analysis plan, and statistical analysis plan are also not reported in the registry record. These are limits on what can be verified from the registry entry; they do not establish that the full study documentation lacked such plans. In addition, other adverse-event denominators and death counts are not reported, limiting interpretation of the safety summaries.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne — NCT00706433.
• Registry record last updated 2011-10-24; status last verified 2011-10.
• Results first posted 2009-08-21.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT00706433 is a completed, randomized, double-masked, parallel-group phase 2 study of aminolevulinic acid or vehicle followed by blue light in moderate to severe facial acne vulgaris. Enrollment was 266. The four arms used ALA or vehicle with 1000-second or 500-second blue-light exposure.

The primary outcome was change in inflammatory lesion counts from baseline to 3 weeks after final treatment, in an ITT analysis with LOCF. The registry reports arm-level medians and standard deviations, and a four-group ANCOVA result of p = 0.768. It does not report pairwise contrasts or confidence intervals for this endpoint. Serious adverse events affected zero participants in each arm; deaths are not reported in the registry record.